HER2 (ERBB2) is a receptor tyrosine kinase that drives proliferative and survival signaling in multiple cancer types. Unlike other ERBB family members, HER2 lacks a confirmed ligand and signals primarily through ligand-induced or constitutive heterodimerization with other ERBB receptors. This review focuses on the molecular architecture of HER2, its dimerization-dependent activation, and the core intracellular signaling cascades—PI3K/AKT, MAPK/ERK, PLCγ, and STAT3—that mediate its oncogenic effects. To support cancer signaling and receptor biology research, we provide flexible and reliable analysis services using protein array technology, meeting diverse needs in cytokine profiling, phosphoprotein detection, and signaling pathway biomarker discovery.
Introduction
HER2 (also known as ERBB2, p185HER2, or NEU) is a 185 kDa receptor tyrosine kinase that belongs to the ERBB family of growth factor receptors, which also includes EGFR (ERBB1), HER3 (ERBB3), and HER4 (ERBB4). The ERBB receptors are type I transmembrane proteins characterized by an extracellular ligand-binding domain, a single transmembrane helix, an intracellular tyrosine kinase domain, and C-terminal tyrosine residues that serve as docking sites for downstream signaling proteins. HER2 occupies a distinctive position within this family: it is the preferred heterodimerization partner for all other ERBB receptors, it exhibits the highest kinase activity among the family, and, uniquely, it has no confirmed high-affinity ligand that binds to its extracellular domain under physiological conditions.
This ligand-independent character fundamentally shapes HER2 biology. In the absence of a dedicated activating ligand, HER2 signaling is governed primarily by its spatial and conformational accessibility to other ERBB receptors, by the availability of ligand-bound partners, and by the intrinsic thermodynamic stability of its active kinase conformation. The oncogenic potential of HER2 is therefore realized through two principal mechanisms: gene amplification leading to surface receptor overexpression, and activating mutations within the kinase or extracellular domains that stabilize the active state. Both mechanisms converge on the same molecular endpoint—sustained, ligand-independent activation of canonical proliferation and survival pathways—and both are actively investigated at the level of receptor structure, dimer interface, and intracellular signal transduction.
Figure 1. Summary of HER family multimerization. (Source: Singh PK, et al. 2024)
HER2 Structure and Dimerization Mechanisms
The molecular architecture of HER2 provides the structural basis for its role as the preferred heterodimerization partner in the ERBB network. The extracellular domain of HER2 consists of four subdomains (I–IV). In the absence of ligand, the extracellular domain adopts a tethered, autoinhibited conformation in EGFR and HER3, in which subdomain IV interacts with subdomain I to block dimerization. HER2, by contrast, crystallizes in a constitutively extended, untethered conformation in which subdomain IV is incapable of engaging the tethering interface. This structural feature makes HER2 constitutively "ready" for dimerization, explaining its high propensity to form heterodimers upon the ligand-induced exposure of complementary binding surfaces on partner receptors.
Dimerization occurs at the level of the extracellular domains and is stabilized by interactions between the receptor that carries the ligand (the "sender") and the ligand-free partner (the "receiver"). HER2 almost invariably acts as the receiver. The HER2-HER3 heterodimer is particularly potent because HER3 contributes six docking sites for the p85 regulatory subunit of PI3K, while HER2 supplies the strongest kinase activity in the family. The thermodynamic stability of this heterodimer, combined with the absence of HER2 internalization in the absence of ligand, results in prolonged signaling duration relative to EGFR-containing dimers, which are subject to ligand-induced endocytosis and degradation.
At the intracellular level, dimerization induces asymmetric kinase domain assembly, in which the C-lobe of the kinase domain of one receptor (the "activator") engages the N-lobe of the kinase domain of the partner (the "receiver"), forcing the activation loop of the receiver into an active conformation. HER2, owing to structural features within its N-lobe, is uniquely effective as an activator kinase, which explains why HER2-containing dimers drive the strongest and most sustained downstream signaling among all ERBB pairings.
Core Intracellular Signaling Cascades
HER2 activation initiates a network of intracellular signaling pathways that converge on cell proliferation, survival, motility, and metabolic reprogramming. The two best-characterized axes are the PI3K/AKT pathway and the MAPK/ERK pathway, both of which are directly activated by phosphorylated tyrosine residues in the C-terminal tail of HER2 and its dimerization partners.
PI3K/AKT/mTOR Axis. HER3 is the principal contributor of PI3K-activating phosphotyrosines within HER2-HER3 dimers. Phosphorylated YXXM motifs in the HER3 C-terminus recruit the p85 regulatory subunit of PI3K, leading to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the inner plasma membrane. PIP3 recruits AKT via its PH domain, where AKT is phosphorylated by PDK1 and mTORC2. Activated AKT phosphorylates a broad array of substrates, including GSK3β, FOXO transcription factors, and mTORC1, promoting protein synthesis, glucose metabolism, and cell survival while suppressing pro-apoptotic programs. The PI3K/AKT axis is the dominant survival pathway driven by HER2 and is a major determinant of therapeutic resistance.
MAPK/ERK Pathway. In contrast to PI3K activation, the MAPK/ERK cascade is initiated primarily through the recruitment of the adaptor protein GRB2, either directly to phosphotyrosines on HER2 or indirectly through SHC. GRB2 brings SOS, a guanine nucleotide exchange factor, to the membrane, where SOS activates KRAS, which in turn initiates the RAF-MEK-ERK kinase cascade. Activated ERK translocates to the nucleus and phosphorylates transcription factors including ELK1, c-FOS, and c-MYC, driving the expression of genes that promote cell cycle progression. Unlike AKT signaling, which is strongly survival-oriented, MAPK/ERK signaling downstream of HER2 is more tightly coupled to proliferative output and is subject to negative feedback through dual-specificity phosphatases such as DUSP family members.
PLCγ and PKC Pathway. HER2 activation also leads to the phosphorylation and activation of phospholipase C gamma (PLCγ), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates protein kinase C (PKC) isoforms, while IP3 mobilizes intracellular calcium stores. This branch of HER2 signaling has been implicated in cell motility, invasion, and the regulation of cell surface receptor trafficking, and it represents an understudied but potentially important component of HER2-driven oncogenesis.
STAT3 Signaling. HER2 activation can lead to the phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3), either directly through JAK family kinases recruited to phosphorylated receptor tyrosines or indirectly through SRC family kinases. Phosphorylated STAT3 dimerizes and translocates to the nucleus, where it drives the expression of genes involved in immune evasion, stemness, and angiogenesis. STAT3 activation downstream of HER2 has been linked to the maintenance of cancer stem cell populations and to resistance to ERBB-targeted therapies.
Figure 2. HER2 signaling pathway. (Source: Feng Y, et al. 2018)
HER2 Ectodomain Shedding and Soluble HER2
An additional layer of molecular regulation is provided by the proteolytic shedding of the HER2 extracellular domain, a process mediated primarily by ADAM family metalloproteases. Shedding generates a soluble form of HER2 (sHER2) that retains the ability to bind to other ERBB receptors and, in some experimental systems, to modulate ligand-induced activation. The molecular determinants of shedding include the proximity of the protease cleavage site to the membrane, the conformational state of the extracellular domain, and the presence of ADAM10 or ADAM17 at the cell surface.
From a signaling perspective, ectodomain shedding has two important consequences. First, it removes the extracellular "brake" that would otherwise keep the receptor in a dimerization-ready but ligand-independent state, potentially altering the kinetics of heterodimer formation. Second, the shed sHER2 fragment can act in trans to compete with membrane-bound HER2 for ligand-bound partners, effectively functioning as a decoy receptor. The quantitative contribution of shedding to net HER2 signaling output in vivo remains an active area of investigation, as does the potential of sHER2 to serve as a pharmacodynamic readout of receptor activation in preclinical models.
HER2 Variants, Splice Isoforms, and Activating Mutations
Beyond the canonical full-length HER2 receptor, several molecular variants have been identified that alter signaling output through changes in dimerization efficiency, kinase activity, or subcellular localization. HER2 splice variants that lack portions of the extracellular domain have been described in gastric and breast cancer specimens and have been shown, in experimental systems, to exhibit enhanced dimerization and increased transforming activity relative to the full-length receptor. The molecular basis of this enhanced signaling is thought to reside in the loss of autoinhibitory extracellular contacts, which renders the variant more constitutively active.
Activating mutations in the HER2 kinase domain have also been discovered in multiple cancer types, including lung adenocarcinomas, gastric cancers, and a subset of breast cancers that lack HER2 gene amplification. These mutations, which cluster in the activation loop, the N-lobe, and the C-lobe of the kinase domain, stabilize the active conformation of the receptor and drive ligand-independent, amplification-independent HER2 signaling. Importantly, many of these mutations confer differential sensitivity to ERBB-targeted kinase inhibitors, providing a molecular rationale for genotype-guided therapeutic strategies. The structural characterization of these mutants has revealed that certain mutations enhance the dimerization interface or alter the ATP-binding pocket in ways that affect both signaling output and drug binding.
More recently, studies have identified HER2 extracellular domain mutations that promote oncogenic activation in the absence of gene amplification. These mutations, located predominantly in subdomain II (the dimerization arm), appear to stabilize the extended, active conformation of the extracellular domain, thereby promoting constitutive dimerization and downstream signaling without changes in gene copy number. The discovery of these mutations has expanded the molecular taxonomy of HER2-driven cancers and underscores the importance of structural and functional studies in interpreting the oncogenic potential of ERBB2 alterations.
Frequently Asked Questions (FAQs)
Unlike EGFR, HER3, and HER4, HER2 does not bind any known EGF-family ligand with high affinity. Structural studies show that the HER2 extracellular domain constitutively adopts an extended, untethered conformation that is incompatible with ligand binding. As a result, HER2 signaling is almost entirely dependent on heterodimerization with ligand-bound partner receptors, which explains why HER2 acts primarily as a "receiver" rather than a "sender" in the ERBB network.
The PI3K/AKT/mTOR axis and the MAPK/ERK pathway are the two dominant cascades activated downstream of HER2-containing dimers. The PI3K/AKT axis is primarily driven by HER3 within HER2-HER3 heterodimers and is the major survival pathway. The MAPK/ERK pathway is initiated through GRB2-SOS-KRAS and drives proliferative gene expression. Additional pathways include PLCγ/PKC and STAT3, which contribute to motility, invasion, and immune modulation.
HER2 splice variants are alternatively spliced isoforms that often lack portions of the extracellular domain. These variants exhibit enhanced dimerization and increased transforming activity in experimental systems because the loss of extracellular autoinhibitory contacts renders them more constitutively active. They have been identified in gastric and breast cancer and may contribute to cases of HER2-driven disease that are not detected by standard amplification-based assays.
Activating mutations in the HER2 kinase domain stabilize the active conformation of the receptor and drive ligand-independent signaling without gene amplification. These mutations cluster in the activation loop and the N- and C-lobes and can alter both signaling output and drug binding. Many mutants exhibit differential sensitivity to ERBB-targeted kinase inhibitors, providing a molecular basis for genotype-guided therapeutic strategies in cancers harboring HER2 mutations.
Yes. Phosphoprotein arrays enable the parallel, quantitative measurement of dozens of signaling nodes—including phosphorylated HER2, AKT, ERK, STAT3, and S6—from a single small-volume sample. This makes it possible to capture the systems-level activation state of the HER2 signaling network and to study pathway cross-talk, feedback, and pharmacodynamic responses in a single integrated workflow.
References
- Singh PK, et al. HER4 is a high-affinity dimerization partner for all EGFR/HER/ErbB family proteins. Protein Sci. 2024 Oct;33(10):e5171.
- Feng Y, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018 May 12;5(2):77-106.
- Hynes NE, et al. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009 Apr;21(2):177-84.
- Chandarlapaty S, et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6784-91.
- Perrier A, et al. The extracellular domain of Her2 in serum as a biomarker of breast cancer. Lab Invest. 2018 Jun;98(6):696-707.
- Barok M, et al. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 2018 May 2;18(1):504.